Darou Darman Arang is a fast growing pharmaceutical Company in Iran.
Darou Darman Arang is a fast growing pharmaceutical Company in Iran.
We are a fast growing pharmaceutical company manufacturing our own brands and representing pharmaceutical companies from around the world in Iran to import medicines.
DAROU DARMAN ARANG acts as the representative agent for specialty, rare disease, biotech and vaccine producing companies looking to penetrate to Iran. We are the preferred strategic partner, providing turn-key solutions and support for their commercial operations…… Read more
We have ensured world-class quality in design, equipment and operations in our manufacturing facility. Our units ensure that we are able to provide best-in-class products to patients across the Iran and emerging markets around. Our manufacturing operations are focused on producing generics and branded generics, in the full range of dosage forms, including tablets, capsules, injectable, pre-filled syringe and freeze dried powder. …… Read more
Imports of Finished Pharmaceuticals
As the pioneer of our mission to meet the needs of the health society across IRAN and beyond with our expert staffs and facilities to import different health care products…… Read more
We in R&D department aimed to Reach to various market requirements and high quality products, by representing formulation and providing new method analysis, taking advantage of experienced Experts, using the most up to dated sources of pharmaceuticals and advanced devices. In addition to exploitation of cooperation and consultation of prominent University professors and other authentic science centers.
Read MoreRegulatory
Having sufficient knowledge of drug registration rules & regulations for registration of products
Adequately capability of registering new products in the Drug National List
Well knowledge of the drug, raw material and food supplement approval process and registration bureaucracy in Ministry of Health
Submitting registration documents to MOH
DAROU DARMAN ARANG COMPANY WAS ESTABLISHED BY A GROUP OF EXPERIENCED PEOPLE TO ATTRACT, DEVELOP AND DELIVER NEW CAPABILITIES.
The European Medicines Agency (EMA) is the body responsible for approval of biosimilars within the European Union (EU). A legal framework for approving biosimilars was established in 2003. Approval of biosimilars is based on an abbreviated registration process, which allows biosimilars manufacturers to provide a reduced package of information compared to originator drugs, provided they can prove ‘similarity’ to the originator or reference drug.
Canada’s drug regulator, Health Canada, has approved the infliximab and filgrastim biosimilars Avsola (ABP 710) and Nivestym.
There are over 200 trials for COVID-19 currently in progress. These include trials of monoclonal antibodies, including from the South Korean firm Celltrion, as well as vaccines, notably from the Chinese firm CanSino Biologics.
